GO
Loading...

Vivus Inc

More

  • Vivus' Mr. Wilson Goes To Washington Monday, 26 Oct 2009 | 2:26 PM ET

    Patients on Vivus' late-stage developmental diet drug, Qnexa, lost an average 37 pounds in 13 months.

  • Cramer makes the call on viewers' favorite stocks.

  • Mad Mail: The Return of US Manufacturing? Friday, 2 Oct 2009 | 9:42 PM ET

    Plus, a call on two speculative drug companies.

  • Lightning Round OT: MBIA, Vivus and More Friday, 2 Oct 2009 | 9:25 PM ET

    The Lightning Round is extended in this CNBC.com exclusive feature.

  • Arena Adds Volume Friday, 18 Sep 2009 | 1:33 PM ET

    There! I resisted writing a blog headline that attempts some tired play on words with the Arena Pharmaceuticals' clinical trial acronyms BLOSSOM and BLOOM.

  • The Qnexa Question Wednesday, 9 Sep 2009 | 5:22 PM ET
    Qnexa

    Some analysts had been telling clients recently that they thought Vivus' diet drug Qnexa could take the lead in the three-contestant race to get the next prescription diet pill on the market. But they didn't think it would take such a commanding lead.

  • Stocks Close Higher Despite Beige Book Wednesday, 9 Sep 2009 | 4:01 PM ET

    Stocks closed higher after faltering for awhile on a Federal Reserve report that the economy will remain weak due largely to unemployment.

  • Stocks Push Higher, Led By Nasdaq, Industrials Wednesday, 9 Sep 2009 | 12:01 PM ET

    Futures indicated a lower open for Wall Street on Wednesday as investors paused ahead of key U.S. data, having pushed markets to 11-month highs the previous day,

  • Commodities Boost Futures; Vivus Soars Wednesday, 9 Sep 2009 | 8:43 AM ET

    Futures indicated a lower open for Wall Street on Wednesday as investors paused ahead of key U.S. data, having pushed markets to 11-month highs the previous day,

  • Biotech Spec: Orexigen Therapeutics Thursday, 13 Aug 2009 | 9:10 PM ET

    This company’s diabetes and obesity drug could generate huge returns for investors.

  • All In The Family Tuesday, 14 Jul 2009 | 11:34 AM ET
    Mike and his sister.

    For years now, but especially in recent months, I've been covering the obesity epidemic. I regularly report on the statistics and the experimental drug data, detached and "objective" as I think any good reporter should be. It just didn't occur to me that the target population might include my sister.

  • Three Down, One To Go Thursday, 4 Jun 2009 | 2:34 PM ET
    Amylin

    In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.

  • Knocked Out Of The Arena Monday, 30 Mar 2009 | 11:27 AM ET

    There is no quid pro quo in my line of work. At least there shouldn't be. But when you do two stories on CNBC and another one on "TODAY" that mentions a company's drug and profiles a patient who appears to have been a "responder" in one of its clinical trials you expect a certain basic professional level of cooperation and assistance.

  • GlaxoSmithKline's New Ally For Alli Friday, 20 Mar 2009 | 11:28 AM ET

    Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.

  • Lilly Gets A Lift, Pfizer Goes Pfft Wednesday, 4 Jun 2008 | 3:05 PM ET

    Despite at least a couple of analysts coming out with relatively bullish post-ASCO research notes on Pfizer's oncology drug pipeline, PFE shares have fallen to yet another new low intra-day and have crossed another threshold.

  • Earnings reports and corporate announcements were some of the catalysts behind the most actively traded stocks on Monday.